Mount Yale Investment Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mount Yale Investment Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,494	Closed	-$310K	–	1207
2026 Q1	$310K	Buy	+5,494	New	+$320K	0.01%	877
2025 Q3	–	Sell	-172	Closed	-$9.46K	–	784
2025 Q2	$9.46K	Buy	+172	New	+$10.1K	﹤0.01%	1144
2018 Q4	–	Sell	-331	Closed	-$33K	–	369
2018 Q3	$33K	Hold	331	–	–	0.01%	683
2018 Q2	$31K	Hold	331	–	–	0.01%	716
2018 Q1	$27K	Buy	+331	New	+$28.4K	0.01%	720

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mount Yale Investment Advisors's BMRN Position: Q2 2026 in Review

Mount Yale Investment Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 5,494 shares — an estimated $310K sold.

Mount Yale Investment Advisors first reported a position in BMRN in Q1 2018 and held it in 5 quarters. The position peaked at $310K in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Mount Yale Investment Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Mount Yale Investment Advisors sold 5,494 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $310K.
Mount Yale Investment Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 5 quarters.
Mount Yale Investment Advisors's BioMarin Pharmaceuticals position peaked at $310K in Q1 2026.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Mount Yale Investment Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.